HIGHLIGHTS
- who: Giulia Meoni and colleagues from the Medical Oncology Unit, Oncology Department, San Giovanni di Dio Hospital, Azienda USL Toscana Centro, Florence, Italy have published the research: Pseudoprogression in lung cancer: a case report, in the Journal: (JOURNAL)
SUMMARY
Solid tumor (RECIST) version 1.1- which are regularly used to assess the efficacy of anticancer agents-are not fully applicable to immunotherapy. This led to the formulation of specific response evaluation criteria such as immune-related response criteria (irRC) proposed in 2009, immune-related RECIST (irRECIST) and immune RECIST (iRECIST), developed respectively in . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.